Please complete this form relating to your transactions for Lannett Company, Inc.(NYSE: LCI) securities between February 7, 2018 and August 17, 2018, inclusive (the “Class Period”).
Once completed, please click the orange “Submit Your Information” button at the bottom of this page. You may also contact James Maro, Jr., Esq. or Adrienne Bell, Esq. at 610.667.7706 or toll free at 888.299.7706, or you may submit your information via email at email@example.com.
Notice is hereby given that a class action lawsuit has been filed on behalf of those who purchased or otherwise acquired Lannett Company, Inc. (“Lannett”) (NYSE: LCI) securities between February 7, 2018 and August 17, 2018, inclusive (the “Class Period”).
According to the complaint, Lannett develops, manufactures, packages, markets and distributes solid oral (tablets and capsules), extended release, topical, and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. At all relevant times, Lannett had an exclusivity agreement with its primary supplier, Jerome Stevens Pharmaceuticals (“JSP”), owned and operated by the Steinlauf family, set to expire on March 23, 2019. JSP’s products have historically accounted for at least one-third of Lannett’s sales.
The Class Period commences on February 7, 2018, when Lannett issued a press release announcing the company’s financial and operating results for the second fiscal quarter ended December 31, 2017.
The complaint alleges that on August 20, 2018, prior to the market opening, Lannett issued a press release stating, in part, “that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed.”
Following this news, Lannett’s share price fell $8.15, or 60.3%, to close at $5.35 on August 20, 2018.
The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (i) Lannett faced a substantial risk of the loss of its exclusivity agreement with JSP; (ii) accordingly, Lannett’s reported revenues were unsustainable; and (iii) as a result, Lannett’s public statements were materially false and misleading at all relevant times.
A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as a lead plaintiff through counsel of their choice, or may choose to do nothing and remain an inactive class member.
Kessler Topaz Meltzer & Check, LLP has not filed a complaint in this matter. If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at firstname.lastname@example.org. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
1-888-299-7706 (toll free) or 1-610-667-7706
Or by e-mail at email@example.com